The Association Between Phosphodiesterase Type 5 Inhibitor Use and Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Meta-Analysis
Authors:
Open Access
- 5 June 2018
- journal article
- review article
- Published by Oxford University Press (OUP) in Sexual Medicine
- Vol. 6 (3) , 185-192
Abstract
Phosphodiesterase type 5 inhibitors (PDE5-Is) are first-line drugs for erectile dysfunction. Non-arteritic anterior ischemic optic neuropathy (NAION) has been linked with PDE5-I use. However, no meta-analysis or conclusive review has explored the association between NAION and PDE5-I use. To investigate the association between PDE5-I use and risk of NAION. A comprehensive literature search was conducted using online databases in October 2017 to obtain studies researching the association between PDE5-I application and occurrence of NAION. Summarized unadjusted risk ratios (RRs) with 95% CIs were calculated for the strength of this association. This study was conducted in accordance to Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines and registered in PROSPERO under number CRD42017080865. The strength of association between PDE5-I use and risk of NAION was assessed through pooled unadjusted RRs and 95% CIs. 5 original articles with 6 clinical observations were included in the meta-analysis. No significant higher risk of NAION was observed after the use of PDE5-Is within a 1-month period (RR = 1.16, 95% CI = 0.98-1.39, P = .09). Subgroup analyses indicated 2 PDE5-Is were significantly related to NAION (tadalafil: RR = 2.14, 95% CI = 1.20–3.84, P = .01; sildenafil: RR = 2.25, 95% CI = 1.29–3.94, P = .004). Although we found no association between NAION and PDE5-I use, our results should be interpreted cautiously because we included only observational studies and could not control for potential confounders. Because NAION is a rare ocular disease and difficult to diagnose, this association should be confirmed in prospective comparative studies with larger samples and more rigorous designs. Liu B, Zhu L, Zhong J, et al. The Association Between Phosphodiesterase Type 5 Inhibitor Use and Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Meta-Analysis. Sex Med 2018;6:185−192.Keywords
Funding Information
- Natural Science Foundation of Guangdong Province (2017A030310547)
- China Postdoctoral Science Foundation (2017M612636, 2017M622912)
This publication has 22 references indexed in Scilit:
- Update on the Safety of Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile DysfunctionSexual Medicine Reviews, 2018
- Erectile Dysfunction Agents and Nonarteritic Anterior Ischemic Optic NeuropathyNeurologic Clinics, 2017
- Cases of Ischemic Optic Neuropathy Associated With Phosphodiesterase-5 Inhibitor Use Reported to the Food and Drug Administration Adverse Event Reporting SystemJournal of Neuro-Ophthalmology, 2016
- Erectile dysfunctionNature Reviews Disease Primers, 2016
- Modifying Risk Factors in the Management of Erectile Dysfunction: A ReviewThe World Journal of Men's Health, 2016
- The Association Between Obstructive Sleep Apnea and Nonarteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Meta-AnalysisCurrent Eye Research, 2015
- Acute Nonarteritic Anterior Ischemic Optic Neuropathy and Exposure to Phosphodiesterase Type 5 InhibitorsThe Journal of Sexual Medicine, 2015
- Erectile dysfunctionThe Lancet, 2013
- Non-arteritic anterior ischaemic optic neuropathy: A review and updateJournal of Clinical Neuroscience, 2009
- Molecular mechanisms of the effects of sildenafil (VIAGRA®)Experimental Gerontology, 1999